Cargando…

Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: a multicenter, retrospective, propensity score-matched study

Corticosteroids use in coronavirus disease 2019 (COVID-19) is controversial, especially in mild to severe patients who do not require invasive/noninvasive ventilation. Moreover, many factors remain unclear regarding the appropriate use of corticosteroids for COVID-19. In this context, this multicent...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, Satoshi, Misumi, Toshihiro, Izumi, Shinyu, Sakamoto, Keita, Nishimura, Naoki, Ro, Shosei, Fukunaga, Koichi, Okamori, Satoshi, Tachikawa, Natsuo, Miyata, Nobuyuki, Shinkai, Masaharu, Shinoda, Masahiro, Miyazaki, Yasunari, Iijima, Yuki, Izumo, Takehiro, Inomata, Minoru, Okamoto, Masaki, Yamaguchi, Tomoyoshi, Iwabuchi, Keisuke, Masuda, Makoto, Takoi, Hiroyuki, Oyamada, Yoshitaka, Fujitani, Shigeki, Mineshita, Masamichi, Ishii, Haruyuki, Nakagawa, Atsushi, Yamaguchi, Nobuhiro, Hibino, Makoto, Tsushima, Kenji, Nagai, Tatsuya, Ishikawa, Satoru, Ishikawa, Nobuhisa, Kondoh, Yasuhiro, Yamazaki, Yoshitaka, Gocho, Kyoko, Nishizawa, Tomotaka, Tsuzuku, Akifumi, Yagi, Kazuma, Shindo, Yuichiro, Takeda, Yuriko, Yamanaka, Takeharu, Ogura, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140087/
https://www.ncbi.nlm.nih.gov/pubmed/34021229
http://dx.doi.org/10.1038/s41598-021-90246-y
_version_ 1783696118595452928
author Ikeda, Satoshi
Misumi, Toshihiro
Izumi, Shinyu
Sakamoto, Keita
Nishimura, Naoki
Ro, Shosei
Fukunaga, Koichi
Okamori, Satoshi
Tachikawa, Natsuo
Miyata, Nobuyuki
Shinkai, Masaharu
Shinoda, Masahiro
Miyazaki, Yasunari
Iijima, Yuki
Izumo, Takehiro
Inomata, Minoru
Okamoto, Masaki
Yamaguchi, Tomoyoshi
Iwabuchi, Keisuke
Masuda, Makoto
Takoi, Hiroyuki
Oyamada, Yoshitaka
Fujitani, Shigeki
Mineshita, Masamichi
Ishii, Haruyuki
Nakagawa, Atsushi
Yamaguchi, Nobuhiro
Hibino, Makoto
Tsushima, Kenji
Nagai, Tatsuya
Ishikawa, Satoru
Ishikawa, Nobuhisa
Kondoh, Yasuhiro
Yamazaki, Yoshitaka
Gocho, Kyoko
Nishizawa, Tomotaka
Tsuzuku, Akifumi
Yagi, Kazuma
Shindo, Yuichiro
Takeda, Yuriko
Yamanaka, Takeharu
Ogura, Takashi
author_facet Ikeda, Satoshi
Misumi, Toshihiro
Izumi, Shinyu
Sakamoto, Keita
Nishimura, Naoki
Ro, Shosei
Fukunaga, Koichi
Okamori, Satoshi
Tachikawa, Natsuo
Miyata, Nobuyuki
Shinkai, Masaharu
Shinoda, Masahiro
Miyazaki, Yasunari
Iijima, Yuki
Izumo, Takehiro
Inomata, Minoru
Okamoto, Masaki
Yamaguchi, Tomoyoshi
Iwabuchi, Keisuke
Masuda, Makoto
Takoi, Hiroyuki
Oyamada, Yoshitaka
Fujitani, Shigeki
Mineshita, Masamichi
Ishii, Haruyuki
Nakagawa, Atsushi
Yamaguchi, Nobuhiro
Hibino, Makoto
Tsushima, Kenji
Nagai, Tatsuya
Ishikawa, Satoru
Ishikawa, Nobuhisa
Kondoh, Yasuhiro
Yamazaki, Yoshitaka
Gocho, Kyoko
Nishizawa, Tomotaka
Tsuzuku, Akifumi
Yagi, Kazuma
Shindo, Yuichiro
Takeda, Yuriko
Yamanaka, Takeharu
Ogura, Takashi
author_sort Ikeda, Satoshi
collection PubMed
description Corticosteroids use in coronavirus disease 2019 (COVID-19) is controversial, especially in mild to severe patients who do not require invasive/noninvasive ventilation. Moreover, many factors remain unclear regarding the appropriate use of corticosteroids for COVID-19. In this context, this multicenter, retrospective, propensity score–matched study was launched to evaluate the efficacy of systemic corticosteroid administration for hospitalized patients with COVID-19 ranging in the degree of severity from mild to critically-ill disease. This multicenter, retrospective study enrolled consecutive hospitalized COVID-19 patients diagnosed January–April 2020 across 30 institutions in Japan. Clinical outcomes were compared for COVID-19 patients who received or did not receive corticosteroids, after adjusting for propensity scores. The primary endpoint was the odds ratio (OR) for improvement on a 7-point ordinal score on Day 15. Of 1092 COVID-19 patients analyzed, 118 patients were assigned to either the corticosteroid and non-corticosteroid group, after propensity score matching. At baseline, most patients did not require invasive/noninvasive ventilation (85.6% corticosteroid group vs. 89.8% non-corticosteroid group). The odds of improvement in a 7-point ordinal score on Day 15 was significantly lower for the corticosteroid versus non-corticosteroid group (OR, 0.611; 95% confidence interval [CI], 0.388–0.962; p = 0.034). The time to improvement in radiological findings was significantly shorter in the corticosteroid versus non-corticosteroid group (hazard ratio [HR], 1.758; 95% CI, 1.323–2.337; p < 0.001), regardless of baseline clinical status. The duration of invasive mechanical ventilation was shorter in corticosteroid versus non-corticosteroid group (HR, 1.466; 95% CI, 0.841–2.554; p = 0.177). Of the 106 patients who received methylprednisolone, the duration of invasive mechanical ventilation was significantly shorter in the pulse/semi-pulse versus standard dose group (HR, 2.831; 95% CI, 1.347–5.950; p = 0.006). In conclusion, corticosteroids for hospitalized patients with COVID-19 did not improve clinical status on Day 15, but reduced the time to improvement in radiological findings for all patients regardless of disease severity and also reduced the duration of invasive mechanical ventilation in patients who required intubation. Trial registration: This study was registered in the University hospital Medical Information Network Clinical Trials Registry on April 21, 2020 (ID: UMIN000040211).
format Online
Article
Text
id pubmed-8140087
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-81400872021-05-25 Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: a multicenter, retrospective, propensity score-matched study Ikeda, Satoshi Misumi, Toshihiro Izumi, Shinyu Sakamoto, Keita Nishimura, Naoki Ro, Shosei Fukunaga, Koichi Okamori, Satoshi Tachikawa, Natsuo Miyata, Nobuyuki Shinkai, Masaharu Shinoda, Masahiro Miyazaki, Yasunari Iijima, Yuki Izumo, Takehiro Inomata, Minoru Okamoto, Masaki Yamaguchi, Tomoyoshi Iwabuchi, Keisuke Masuda, Makoto Takoi, Hiroyuki Oyamada, Yoshitaka Fujitani, Shigeki Mineshita, Masamichi Ishii, Haruyuki Nakagawa, Atsushi Yamaguchi, Nobuhiro Hibino, Makoto Tsushima, Kenji Nagai, Tatsuya Ishikawa, Satoru Ishikawa, Nobuhisa Kondoh, Yasuhiro Yamazaki, Yoshitaka Gocho, Kyoko Nishizawa, Tomotaka Tsuzuku, Akifumi Yagi, Kazuma Shindo, Yuichiro Takeda, Yuriko Yamanaka, Takeharu Ogura, Takashi Sci Rep Article Corticosteroids use in coronavirus disease 2019 (COVID-19) is controversial, especially in mild to severe patients who do not require invasive/noninvasive ventilation. Moreover, many factors remain unclear regarding the appropriate use of corticosteroids for COVID-19. In this context, this multicenter, retrospective, propensity score–matched study was launched to evaluate the efficacy of systemic corticosteroid administration for hospitalized patients with COVID-19 ranging in the degree of severity from mild to critically-ill disease. This multicenter, retrospective study enrolled consecutive hospitalized COVID-19 patients diagnosed January–April 2020 across 30 institutions in Japan. Clinical outcomes were compared for COVID-19 patients who received or did not receive corticosteroids, after adjusting for propensity scores. The primary endpoint was the odds ratio (OR) for improvement on a 7-point ordinal score on Day 15. Of 1092 COVID-19 patients analyzed, 118 patients were assigned to either the corticosteroid and non-corticosteroid group, after propensity score matching. At baseline, most patients did not require invasive/noninvasive ventilation (85.6% corticosteroid group vs. 89.8% non-corticosteroid group). The odds of improvement in a 7-point ordinal score on Day 15 was significantly lower for the corticosteroid versus non-corticosteroid group (OR, 0.611; 95% confidence interval [CI], 0.388–0.962; p = 0.034). The time to improvement in radiological findings was significantly shorter in the corticosteroid versus non-corticosteroid group (hazard ratio [HR], 1.758; 95% CI, 1.323–2.337; p < 0.001), regardless of baseline clinical status. The duration of invasive mechanical ventilation was shorter in corticosteroid versus non-corticosteroid group (HR, 1.466; 95% CI, 0.841–2.554; p = 0.177). Of the 106 patients who received methylprednisolone, the duration of invasive mechanical ventilation was significantly shorter in the pulse/semi-pulse versus standard dose group (HR, 2.831; 95% CI, 1.347–5.950; p = 0.006). In conclusion, corticosteroids for hospitalized patients with COVID-19 did not improve clinical status on Day 15, but reduced the time to improvement in radiological findings for all patients regardless of disease severity and also reduced the duration of invasive mechanical ventilation in patients who required intubation. Trial registration: This study was registered in the University hospital Medical Information Network Clinical Trials Registry on April 21, 2020 (ID: UMIN000040211). Nature Publishing Group UK 2021-05-21 /pmc/articles/PMC8140087/ /pubmed/34021229 http://dx.doi.org/10.1038/s41598-021-90246-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Ikeda, Satoshi
Misumi, Toshihiro
Izumi, Shinyu
Sakamoto, Keita
Nishimura, Naoki
Ro, Shosei
Fukunaga, Koichi
Okamori, Satoshi
Tachikawa, Natsuo
Miyata, Nobuyuki
Shinkai, Masaharu
Shinoda, Masahiro
Miyazaki, Yasunari
Iijima, Yuki
Izumo, Takehiro
Inomata, Minoru
Okamoto, Masaki
Yamaguchi, Tomoyoshi
Iwabuchi, Keisuke
Masuda, Makoto
Takoi, Hiroyuki
Oyamada, Yoshitaka
Fujitani, Shigeki
Mineshita, Masamichi
Ishii, Haruyuki
Nakagawa, Atsushi
Yamaguchi, Nobuhiro
Hibino, Makoto
Tsushima, Kenji
Nagai, Tatsuya
Ishikawa, Satoru
Ishikawa, Nobuhisa
Kondoh, Yasuhiro
Yamazaki, Yoshitaka
Gocho, Kyoko
Nishizawa, Tomotaka
Tsuzuku, Akifumi
Yagi, Kazuma
Shindo, Yuichiro
Takeda, Yuriko
Yamanaka, Takeharu
Ogura, Takashi
Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: a multicenter, retrospective, propensity score-matched study
title Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: a multicenter, retrospective, propensity score-matched study
title_full Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: a multicenter, retrospective, propensity score-matched study
title_fullStr Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: a multicenter, retrospective, propensity score-matched study
title_full_unstemmed Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: a multicenter, retrospective, propensity score-matched study
title_short Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: a multicenter, retrospective, propensity score-matched study
title_sort corticosteroids for hospitalized patients with mild to critically-ill covid-19: a multicenter, retrospective, propensity score-matched study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140087/
https://www.ncbi.nlm.nih.gov/pubmed/34021229
http://dx.doi.org/10.1038/s41598-021-90246-y
work_keys_str_mv AT ikedasatoshi corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT misumitoshihiro corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT izumishinyu corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT sakamotokeita corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT nishimuranaoki corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT roshosei corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT fukunagakoichi corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT okamorisatoshi corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT tachikawanatsuo corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT miyatanobuyuki corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT shinkaimasaharu corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT shinodamasahiro corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT miyazakiyasunari corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT iijimayuki corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT izumotakehiro corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT inomataminoru corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT okamotomasaki corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT yamaguchitomoyoshi corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT iwabuchikeisuke corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT masudamakoto corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT takoihiroyuki corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT oyamadayoshitaka corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT fujitanishigeki corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT mineshitamasamichi corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT ishiiharuyuki corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT nakagawaatsushi corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT yamaguchinobuhiro corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT hibinomakoto corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT tsushimakenji corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT nagaitatsuya corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT ishikawasatoru corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT ishikawanobuhisa corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT kondohyasuhiro corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT yamazakiyoshitaka corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT gochokyoko corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT nishizawatomotaka corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT tsuzukuakifumi corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT yagikazuma corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT shindoyuichiro corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT takedayuriko corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT yamanakatakeharu corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy
AT oguratakashi corticosteroidsforhospitalizedpatientswithmildtocriticallyillcovid19amulticenterretrospectivepropensityscorematchedstudy